{"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.\n\nNOTE: \\*After one year of treatment, dexamethasone is tapered for an additional 4 weeks.\n\nClarithromycin: Given Orally (PO)\n\nDexamethasone: Given PO\n\nLenalidomide: Given PO","id":"BG000","title":"Treatment (Clarithromycin, Dexamethasone, Lenalidomide)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"72","value":"58"}]}]}],"description":"Age at transplant","dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"28"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}